Goldman Sachs Maintains Neutral on Bicara Therapeutics, Raises Price Target to $16
Benzinga Newsdesk 7 months ago
NewsPrice TargetAnalyst Ratings
Goldman Sachs analyst Richard Law maintains Bicara Therapeutics (NASDAQ:BCAX) with a Neutral and raises the price target from $14 to $16.
Goldman Sachs analyst Richard Law maintains Bicara Therapeutics (NASDAQ:BCAX) with a Neutral and raises the price target from $14 to $16.